Literature DB >> 31117077

Cardiac Resynchronization Therapy Optimization: A Comprehensive Approach.

Asim Katbeh1,2, Guy Van Camp1, Emanuele Barbato1,2, Maurizio Galderisi2, Bruno Trimarco2, Jozef Bartunek1, Marc Vanderheyden1, Martin Penicka3.   

Abstract

Since the first report on biventricular pacing in 1994, cardiac resynchronization therapy (CRT) has become standard for patients with advanced heart failure (HF) and ventricular conduction delay. CRT improves myocardial function by resynchronizing myocardial contraction, which results in reverse left ventricular remodeling and improves symptoms and clinical outcomes. Despite the accelerated development of CRT device technology and its increased application in treating HF patients, almost one-third of these patients do not respond to the therapy or gain any clinical benefit from device implantation. Over the last decade, multiple cardiac imaging modalities have provided a deeper understanding of myocardial pathophysiology, thereby improving HF treatment management. However, the optimal strategy for improving the CRT response remains debatable. This article provides an updated overview of the electropathophysiology of myocardial dysfunction in ventricular conduction delay and the diagnostic approaches involving the use of multiple modalities.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Cardiac dyssynchrony; Cardiac resynchronization; Heart failure; Myocardial dysfunction; Therapy optimization

Year:  2019        PMID: 31117077     DOI: 10.1159/000499192

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  2 in total

1.  Left Bundle Branch Area Pacing vs. Biventricular Pacing for Cardiac Resynchronization Therapy: A Meta-Analysis.

Authors:  Jiyi Liu; Fengzhi Sun; Zefeng Wang; Jiao Sun; Xue Jiang; Weilong Zhao; Zhipeng Zhang; Lu Liu; Shulong Zhang
Journal:  Front Cardiovasc Med       Date:  2021-05-24

2.  Systematic Pharmacology Reveals the Antioxidative Stress and Anti-Inflammatory Mechanisms of Resveratrol Intervention in Myocardial Ischemia-Reperfusion Injury.

Authors:  Zuzhong Xing; Qi He; Yinliang Xiong; Xiaomei Zeng
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-21       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.